Wells Fargo & Company Brooklyn Immuno Therapeutics, Inc. Transaction History

Wells Fargo & Company

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$0.23 - $0.71 $21 - $66	93 Added 22.14%	513 $0
Q2 2022 Aug 12, 2022	SELL	$0.48 - $2.03 $23,474 - $99,277	-48,905 Reduced 99.15%	420 $0
Q1 2022 May 16, 2022	SELL	$1.76 - $4.84 $13,691 - $37,650	-7,779 Reduced 13.62%	49,325 $101,000
Q4 2021 Feb 14, 2022	BUY	$4.17 - $9.79 $120,917 - $283,880	28,997 Added 103.17%	57,104 $238,000
Q3 2021 Nov 15, 2021	BUY	$8.86 - $17.05 $247,149 - $475,609	27,895 Added 13158.02%	28,107 $261,000
Q2 2021 Aug 16, 2021	BUY	$3.75 - $78.5 $723 - $15,150	193 Added 1015.79%	212 $4,000
Q1 2021 May 13, 2021	BUY	$3.72 - $12.76 $70 - $242	19 New	19 $0

1.21M

Ticker BTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,825,700
Description
Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy techno...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.